Kazia Therapeutics Unveils Promising Data for Novel Nuclear PD-L1 Degrader NDL2
Kazia Therapeutics, a Sydney-based pharmaceutical company specializing in oncology, has announced significant findings from its research on NDL2, a groundbreaking nuclear PD-L1 degrader. This innovative approach targets nuclear PD-L1, a newly identified factor in immunotherapy resistance, addressing a critical gap left by existing therapies that focus on extracellular interactions.
The data was developed in collaboration with Professor Sudha Rao at QIMR Berghofer and presents a compelling case for NDL2’s potential effectiveness in treating aggressive cancers. The research indicates that nuclear PD-L1 plays a crucial role in promoting:
Within preclinical studies, NDL2 demonstrated notable results, including a significant reduction in tumor volume in triple-negative breast cancer (TNBC) models—49% when used alone and a remarkable 73% in combination with anti-PD-1 therapy. Moreover, there was a 50% decrease in lung metastases observed with the combination treatment, which highlights NDL2's potential to improve outcomes for cancer patients who are typically resistant to existing treatments.
One of the most exciting aspects of Kazia's findings is the favorable safety profile of NDL2 during preclinical testing. No adverse toxicities or hemolysis were detected, and the compound preserved immune checkpoint functions on cell surfaces while showing stability in the circulation—a critical factor in drug development.
In addition to its therapeutic potential, the findings advocate for using NDL2 as a predictive biomarker for patient response to treatment. Researchers utilized advanced pathology technologies to determine that nuclear PD-L1 is more prevalent in resistant tumors across various types—such as TNBC, melanoma, and non-small cell lung cancer—showing that targeting this form of PD-L1 could significantly enhance treatment efficacy.
The implications of these results are wide-ranging. By leveraging targeted protein degradation, Kazia is addressing a growing area of interest within oncology and solidifying its position as a pioneer in developing therapies that specifically tackle previously overlooked cellular mechanisms.
Kazia's strategy to approach PD-L1 degradation presents a significant shift toward targeting intracellular proteins, offering a more robust avenue of treatment against cancers that have previously shown resilience against standard therapies. With PD-L1 being one of the most extensively validated targets in cancer therapy, understanding its role in immune evasion can lead to significant breakthroughs in cancer therapy.
Kazia is gearing up to move forward with the development of NDL2. The company aims to initiate first-in-human trials in 2027, pending regulatory approvals. The strategic focus will be on immunotherapy-refractory solid tumors where PD-L1's function is well established. This includes cancers known for their aggressive nature, like TNBC and melanoma.
Excitingly, Kazia also plans to share more insights at an upcoming scientific conference set for the second quarter of 2026. Attendees can expect in-depth discussions about the biological mechanisms behind NDL2’s success and further translational data that solidifies its therapeutic rationale. The upcoming corporate presentation in the first quarter of 2026 will also highlight additional advancements and potential collaborations as Kazia's innovative trajectory unfolds.
In the words of Kazia’s CEO, Dr. John Friend, “Targeted protein degradation offers transformative opportunities in oncology. By focusing on PD-L1 degradation, we aim to address resistance mechanisms in cancer that current therapies struggle with, potentially opening new pathways for effective treatment.”
The data was developed in collaboration with Professor Sudha Rao at QIMR Berghofer and presents a compelling case for NDL2’s potential effectiveness in treating aggressive cancers. The research indicates that nuclear PD-L1 plays a crucial role in promoting:
- - Epithelial to Mesenchymal Transition (EMT), leading to more aggressive cancer characteristics.
- - Cancer stem-like phenotypes, which contribute to tumor recurrence and resistance.
- - Metastatic spread and immune evasion, exacerbating treatment challenges for patients.
Within preclinical studies, NDL2 demonstrated notable results, including a significant reduction in tumor volume in triple-negative breast cancer (TNBC) models—49% when used alone and a remarkable 73% in combination with anti-PD-1 therapy. Moreover, there was a 50% decrease in lung metastases observed with the combination treatment, which highlights NDL2's potential to improve outcomes for cancer patients who are typically resistant to existing treatments.
One of the most exciting aspects of Kazia's findings is the favorable safety profile of NDL2 during preclinical testing. No adverse toxicities or hemolysis were detected, and the compound preserved immune checkpoint functions on cell surfaces while showing stability in the circulation—a critical factor in drug development.
In addition to its therapeutic potential, the findings advocate for using NDL2 as a predictive biomarker for patient response to treatment. Researchers utilized advanced pathology technologies to determine that nuclear PD-L1 is more prevalent in resistant tumors across various types—such as TNBC, melanoma, and non-small cell lung cancer—showing that targeting this form of PD-L1 could significantly enhance treatment efficacy.
The implications of these results are wide-ranging. By leveraging targeted protein degradation, Kazia is addressing a growing area of interest within oncology and solidifying its position as a pioneer in developing therapies that specifically tackle previously overlooked cellular mechanisms.
Kazia's strategy to approach PD-L1 degradation presents a significant shift toward targeting intracellular proteins, offering a more robust avenue of treatment against cancers that have previously shown resilience against standard therapies. With PD-L1 being one of the most extensively validated targets in cancer therapy, understanding its role in immune evasion can lead to significant breakthroughs in cancer therapy.
Kazia is gearing up to move forward with the development of NDL2. The company aims to initiate first-in-human trials in 2027, pending regulatory approvals. The strategic focus will be on immunotherapy-refractory solid tumors where PD-L1's function is well established. This includes cancers known for their aggressive nature, like TNBC and melanoma.
Excitingly, Kazia also plans to share more insights at an upcoming scientific conference set for the second quarter of 2026. Attendees can expect in-depth discussions about the biological mechanisms behind NDL2’s success and further translational data that solidifies its therapeutic rationale. The upcoming corporate presentation in the first quarter of 2026 will also highlight additional advancements and potential collaborations as Kazia's innovative trajectory unfolds.
In the words of Kazia’s CEO, Dr. John Friend, “Targeted protein degradation offers transformative opportunities in oncology. By focusing on PD-L1 degradation, we aim to address resistance mechanisms in cancer that current therapies struggle with, potentially opening new pathways for effective treatment.”
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.